24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
More Social Media Use, More Fake COVID NewsSkip the 'Maskne,' Not the MaskObesity Ups Odds for Severe COVID-19, But Age MattersSeven States Join Pact to Speed Coronavirus TestingStudy Casts Doubt on Value of Cholesterol DrugsCOVID-19 Fears Had Sick, Injured Americans Avoiding ERsCancer Diagnoses Plunge as Americans Avoid Screening During PandemicMysterious Paralyzing Illness in Kids Is Set to Return, CDC WarnsMany Older Americans Staying Strong in the PandemicCoronavirus Cases Now Climbing in the MidwestCould the First Drug That Slows Arthritis Be Here?Schools Can Reopen Safely If Precautions in Place, Australian Study ShowsFace Masks, Yes, But Don't Forget Hand-Washing TooEven With PPE, Risk of COVID-19 Still High for Frontline WorkersCoronavirus Pandemic Becoming Far More Widespread, Birx SaysGuard Against Lyme Disease This SummerKids 'Efficient' Transmitters as COVID-19 Raced Through a Georgia Summer CampCollege Students Will Need COVID Tests Every 2-3 Days for Campus Safety: StudyAHA News: Sustained High Blood Pressure May Damage Brain VesselsAnother Side Effect of COVID-19 -- Lasting Hearing Problems?Pandemic Could Complicate Hurricane SeasonStudy Reveals How Coronavirus Travels IndoorsNew Study Sheds Doubt on Notion Kids Aren't COVID-19 SpreadersAHA News: Are Virtual Doctor Visits Safe for Discharged Heart Failure Patients?Double Lung Transplants Save Lives of Sickest COVID PatientsGynecological Cancers Not a Risk for Severe COVID-19: Study11 States Could Face ICU Doc Shortages as Coronavirus Cases SurgeWildfire Pollution Puts Kidney Patients at RiskAmerica's Progress Against Early Cardiovascular Death Is SlowingAHA News: 5 Easy Ways to Keep Tabs on Heart HealthGene Study Shows How Coronavirus Swept Through the Diamond PrincessOne Disease Mosquitoes Don't Spread: CoronavirusU.S. Coronavirus Death Toll Surges Past 150,000Do Bedbugs Dirty the Air Inside Your Home?AHA News: New Test May Predict Who Develops Certain Type of Heart FailureLess Smoking, Drinking Means Fewer Hip Fractures for AmericansYet Another Study Finds Vaccines Are SafeCommon Diabetes Meds Linked to Higher Odds for a Serious ComplicationSurvivors' COVID Antibodies May Provide a Powerful GiftConcussion Ups Odds for Many Brain ConditionsFinal Coronavirus Vaccine Trials Get UnderwayAHA News: Flu Shot May Help Protect Vulnerable Hospital Patients From Heart Attack, Mini-StrokeCOVID-19 'Super Spreaders' Quickly Fill Room With Virus -- But Masks HelpIn Rush to Publish, Most COVID-19 Research Isn't Reliable, Experts SayGlaucoma Checkups Fall by the Wayside During PandemicLab-Created Virus Can Help COVID-19 Research, Developers SayHow to Counter the Anti-Mask Backlash? Empathy.States With Soaring COVID Cases Must Take Action, U.S. Health Officials SayWhat Puts You at High Risk of Midlife Mental Decline?AHA News: Controlling Diabetes Takes on Greater Urgency During COVID-19 Pandemic
Questions and AnswersLinks
Related Topics

Diabetes

3 Drugs for Severe Epileptic Seizures Are Equally Effective: Study

HealthDay News
by -- Robert Preidt
Updated: Dec 5th 2019

new article illustration

THURSDAY, Dec. 5, 2019 (HealthDay News) -- Three drugs used to treat severe seizures in epilepsy patients are equally effective, a new study finds.

The three medications -- levetiracetam (Keppra and Roweepra), fosphenytoin (Cerebyx) and valproate -- are commonly used to treat patients with "refractory status epilepticus." In these patients, severe seizures continue after treatment with benzodiazepine medications.

The study of 380 emergency department patients compared the three drugs' effectiveness in stopping seizures and improving patients' levels of responsiveness within 60 minutes. The patients included children and adults.

The three treatments stopped seizures and improved responsiveness in about half of the patients: 47% in the levetiracetam group; 45% in the fosphenytoin group; and 46% in the valproate group. Researchers said the differences were not statistically significant.

The three drugs had no differences in serious side effects, according to the study published Nov. 28 in the New England Journal of Medicine.

The research was supported by the U.S. National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.

"Doctors can be confident that the particular treatment they choose for their patients with status epilepticus is safe and effective, and may help them avoid the need to intubate the patient as well as stays in the intensive care unit," study co-author Dr. Robin Conwit, NINDS program director, said in an agency news release.

Study co-leader Dr. Robert Silbergleit said the study suggests that clinical outcomes are driven by factors other than drugs.

"Differences in how doctors decide to treat status epilepticus, such as when they give more drugs or when to anesthetize patients and put them on a mechanical ventilator, may be more important than the specific treatments used to control seizures in patients," said Silbergleit, a professor of emergency medicine at the University of Michigan in Ann Arbor.

In status epilepticus, seizures occur close together and last more than 5 minutes, with a loss of consciousness. If not treated, patients can suffer severe brain damage or die. Benzodiazepines are effective in two-thirds of patients.

More information

The American Academy of Family Physicians has more on epilepsy.